From state Prescription Drug Affordability Board (PDAB) action to the implementation of the Inflation Reduction Act (IRA), state and federal price-setting policies do little to solve barriers to care for historically underserved communities that are disproportionately impacted by chronic conditions.

Instead, they put access to medicines at risk while letting insurers and pharmacy benefit managers (PBMs) off the hook by allowing them to pocket tens of billions in drug manufacturer rebates and discounts that should be going to patients at the pharmacy counter.